During the past year, the VRC's Vector Core created and tested new vaccine vectors expressing different HIV protein, including novel forms of envelope proteins. In addition,different methods and routes of administration as well as prime/boost combinations were tested to further optimize HIV vaccine strategies. DNA, VLP and other vectors were tested. Several candidate vaccines elicited promising immunogenicity data in preliminary studies and are being tested further. Specific accomplishments include: Continued assessment of recombinant Chimp adenovirus vectors as a vaccine to prevent HIV infections. Different prime boost vectors encoding HIV-1 Env including DNA, non human primate adenoviruses and alternative serotype rAd for priming followed by boosting with replication-defective vectors were compared. T cell immunogenicity was assessed by intracellular cytokine staining or by analyzing tetramer positive cells. Studies to optimize the CD4-binding site (CD4bs) as a basis for vaccine development were continued. The HIV Outer domain (OD) of gp120 envelope is a minimal unit containing the CD4bs which is targeted by broadly neutralizing antibodies, VRC01 and b12, therefore thought to be an attractive immunogen to induce such antibodies. During the past year studies continued to engineer the OD and other epitopes on the CD4bs to optimize their use as immunogens. In addition, ferritin nanoparticles experssing HIV envelope were analyzed to induce CD4bs antibodies, identified by newly developed assays based on the resurfaced stabilized gp120 core with antigenic specificity for the initial site of CD4 attachment of gp120. Epitopes recognized by vectors expressing neutralizing antibodies were also analyzed and tested for their ability to induce similar types of antibodies, in vivo.

Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Zip Code
Cheng, Cheng; Pancera, Marie; Bossert, Adam et al. (2016) Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody. J Virol 90:2740-55
Saunders, Kevin O; Pegu, Amarendra; Georgiev, Ivelin S et al. (2015) Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection. J Virol 89:5895-903
Lynch, Rebecca M; Wong, Patrick; Tran, Lillian et al. (2015) HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies. J Virol 89:4201-13
Georgiev, Ivelin S; Joyce, M Gordon; Yang, Yongping et al. (2015) Single-Chain Soluble BG505.SOSIP gp140 Trimers as Structural and Antigenic Mimics of Mature Closed HIV-1 Env. J Virol 89:5318-29
Cheng, Cheng; Wang, Lingshu; Ko, Sung-Youl et al. (2015) Combination recombinant simian or chimpanzee adenoviral vectors for vaccine development. Vaccine 33:7344-51
Pegu, Amarendra; Yang, Zhi-yong; Boyington, Jeffrey C et al. (2014) Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci Transl Med 6:243ra88
Ko, Sung-Youl; Pegu, Amarendra; Rudicell, Rebecca S et al. (2014) Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature 514:642-5
Pancera, Marie; Zhou, Tongqing; Druz, Aliaksandr et al. (2014) Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature 514:455-61
Corey, Lawrence; Nabel, Gary J; Dieffenbach, Carl et al. (2011) HIV-1 vaccines and adaptive trial designs. Sci Transl Med 3:79ps13
Sastry, Mallika; Xu, Ling; Georgiev, Ivelin S et al. (2011) Mammalian production of an isotopically enriched outer domain of the HIV-1 gp120 glycoprotein for NMR spectroscopy. J Biomol NMR 50:197-207

Showing the most recent 10 out of 13 publications